Streetwise Management Q&As


Radioimmunotherapy 2.0: Actinium Sets Eyes on Bone Marrow Transplant and AML with Later-Stage Programs
Source: The Life Sciences Report  (8/17/16)
Radioimmunotherapy is experiencing a renaissance, and Actinium Pharmaceuticals Inc. is in position to benefit, according to company executive chairman Sandesh Seth. With two assets targeting treatment of AML in older adults in clinical trials, and a platform primed to "nuke cancer," the company has a number of milestones in its near future that investors should be watching. More >


Punit Dhillon

OncoSec Delivers Cancer Therapy Straight to the Tumor
Source: Special to The Life Sciences Report  (6/1/16)
Cancer patients often receive multiple rounds of chemotherapy, with new drugs incorporated into treatment programs as tumors develop resistance. OncoSec Medical Incorporated's Punit Dhillon describes how his company is challenging that paradigm with a proprietary platform that delivers therapeutic agents directly to the tumor, while also laying a foundation for expanded use of combination immunotherapies at the forefront of cancer treatment. More >


Kolin Ozonian

How Nobilis Health Will Break Out of the Healthcare Payment Mold
Source: George S. Mack of The Life Sciences Report   (5/25/16)
Managing both acquisitions and internal growth at the same time is difficult for most small companies, akin to drinking water and singing at the same time. Not so for Nobilis Health Corp., which is orchestrating the flow of new patients to its ambulatory surgical centers while it adds an ensemble of new clinics, resulting in harmonious revenue. The conductor is merger-and-acquisition specialist Kolin Ozonian, who brings years of business development experience in large-cap healthcare to this small-cap enterprise. In this interview with The Life Sciences Report, Ozonian discusses his company's newest technology and talks about how Nobilis will achieve critical mass. More >


Domenic Della Penna

Dialing Back Euphoria: The Intellipharmaceutics Prescription for Opioid Abuse
Source: Special to The Life Sciences Report  (5/11/16)
Opioid abuse has moved front and center in the political and social arena, sparked in recent weeks by the still-unexplained death of music legend Prince. Heroin is the headline, but addiction to prescription painkillers, like those reportedly used by the pop icon to control chronic pain, runs a close second. How can the biotech industry deter abuse of drugs like oxycodone? Intellipharmaceutics International has a potential solution, Chief Financial Officer Domenic Della Penna tells The Life Sciences Report, as well as a robust pipeline of generic options for a variety of indications. More >


James Joyce

Exosome Sciences Uncovers Biomarker Candidate to ID Players with CTE
Source: Special to The Life Sciences Report  (5/4/16)
Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc., is developing an exosome-based platform to diagnose a broad-spectrum of disease conditions. In this interview with The Life Sciences Report, Executive Chairman James "Jim" Joyce shares the initial clinical results of a biomarker study to diagnose chronic traumatic encephalopathy (CTE), a neurodegenerative disorder often found in professional football players through postmortem autopsy. Mr. Joyce reports on the discovery of a TauSome™ biomarker found to be 9x higher, on average, in former National Football League players as compared to control subjects. Exosome Sciences believes its TauSome test may be the first noninvasive candidate to diagnose CTE in living individuals. More >


Christopher Schaber

Soligenix Fosters Potent Pipeline of Orphan Disease Compounds in Areas of Unmet Medical Need
Source: Special to The Life Sciences Report  (4/27/16)
With a robust pipeline of drugs in late-stage clinical trials and milestones on the horizon, it's no wonder Soligenix Inc.'s CEO, Dr. Christopher Schaber, holds an optimistic view of the company's future. Two candidates targeting orphan diseases—a type of lymphoma and pediatric Crohn's disease—are in Phase 3, a treatment for oral mucositis is in Phase 2, and Soligenix's biodefense vaccine and therapeutic platform is backed by significant government funding. In this interview with The Life Sciences Report, Dr. Schaber expands on the status of the company's portfolio. More >


Michael Becker

Relmada Therapeutics Launches Pharmaceutical Armada Against Chronic Pain and Opioid Abuse
Source: Special to The Life Sciences Report  (4/20/16)
To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. has a small fleet of compounds in development that address both sides of an issue that has become a newsmaker, given the recent upsurge in heroin addiction and the ever-present conundrum of alleviating severe pain in chronic disease and after surgery. In this interview with The Life Sciences Report, Relmada's Michael Becker describes the company's programs, which are advancing steadily toward the marketplace.
More >


Frank Oakes

Stellar Biotechnologies: Cures for Cancer, Alzheimer's Disease, Lupus, and More Underscore the Critical Need to Protect Oceans
Source: Staff of The Life Sciences Report  (4/5/16)
Frank Oakes, the chairman, president and CEO of Stellar Biotechnologies, has a passion for the potential life-saving cures the ocean may provide. His company, a world leader in the production of sustainable, scalable and fully traceable GMP-grade KLH protein, has established research and manufacturing facilities along the Pacific Ocean to produce KLH, and Oakes himself has more than three decades of management experience in aquaculture. In this interview with The Life Sciences Report, Oakes talks about how he got involved in this exciting and emerging space, and describes the potential Stellar KLH has in the burgeoning field of immunotherapy. More >


David Kalergis

Diffusion Pharmaceuticals Takes Aim at Brain Cancer: CEO David Kalergis
Source: George S. Mack of The Life Sciences Report  (3/30/16)
It takes extraordinary dexterity to execute a strategic merger, and then to take first steps toward positioning a new molecular entity for a Phase 3 drug trial and potential partnership with a big pharma. That's exactly the inflection point at which Diffusion Pharmaceuticals Inc. finds itself, says CEO David Kalergis. In this interview with The Life Sciences Report, Kalergis lays out Diffusion's plan for pivotal development of its treatment for primary brain cancer, which could drive the company's market cap to valuations that would bring huge upside to investors if successful. More >


Lisa Crossley

Moseda Joins Telus and Apple in the $20B Patient Home Monitoring Sector
Source: Special to The Life Sciences Report  (3/29/16)
Because chronic conditions are difficult to manage by patients at home, with complications, hospitalizations and other expensive interventions sometimes necessary, they account for more than 75% of healthcare costs worldwide. To meet this need, Moseda Technologies has developed innovative, secure mobile software solutions for the $20 billion community/home care market. In this interview with The Life Sciences Report, Moseda's CEO, Dr. Lisa Crossley, describes the company's comprehensive hardware and software solution, dubbed CareKit, which allows patients to receive high-quality care in the home, improving health outcomes and enhancing quality of life for patients and families while reducing the cost of care. More >


Kolin Ozonian

Nobilis Health Doubles Down, Offering Organic Growth and Aggressive Acquisitions: Kolin Ozonian
Source: George S. Mack of The Life Sciences Report  (3/23/16)
Businesses can grow in two ways—internally and externally. Nobilis Health Corp. has a voracious appetite for both. The company is a development and management firm that acquires private outpatient surgical centers—in short, it's a business model built on efficiencies. Nobilis scans the market for clinics that can be acquired and scaled up using sophisticated direct marketing approaches. In this interview with The Life Sciences Report, Nobilis' mergers-and-acquisitions specialist Kolin Ozonian talks about the business model and tells investors how he and the Nobilis team plan to aggressively grow the company. More >


CorMedix Transformative Anti-Infective Technology for Catheters Developed to Decrease Serious Drug-Resistant Infections: CEO Randy Milby
Source: George S. Mack of The Life Sciences Report  (2/11/16)
Patients on dialysis and cancer patients with indwelling catheters live with the possibility of contracting drug-resistant infections that can become more life threatening than their primary diseases. CorMedix Inc. (CRMD:NYSE.MKT) is developing a platform that has shown impressive results in preventing serious bloodstream infections. In this interview with The Life Sciences Report, CorMedix CEO Randy Milby addresses his company's science, pipeline and market opportunity. Chief Scientific Officer and Cofounder Antony Pfaffle, an internist who practiced nephrology, joins the conversation to relate his experience managing chronically ill patients undergoing catheter-based therapies in the critical care setting. More >


Stewart Washer

Advanced Stem Cell Manufacture Saves Lives and Prints Money: Stewart Washer of Cynata Therapeutics
Source: Peter Byrne of The Life Sciences Report  (2/3/16)
Cynata Therapeutics of Australia has carved a technological niche in the fast-advancing cell therapy market with a platform that renders the production of stem cell-based treatments for cancer and diseases of the immune system easy and affordable, saving lives and money. In this interview, Cynata's executive chairman Stewart Washer tells The Life Sciences Report why his company's technology, in studies for graft-versus-host disease, has proven itself a profit driver. More >


Leo Ehrlich

A Small-Cap Biotech with Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and Dr. Daniel Jorgensen
Source: George S. Mack of The Life Sciences Report  (1/27/16)
Drug development seems to move at a snail's pace, but Cellceutix Corp.'s CEO Leo Ehrlich says his company has jumped through the most time-consuming hoops of development and now has a diversified pipeline with three main drug candidates, any of which could become the lead program with new data in 2016. Ehrlich and Chief Medical Officer Dr. Daniel Jorgensen, an infectious disease specialist, discuss the candidates, beginning with the first new class of antibiotics to enter Phase 3 in skin infections in decades. More >


James Brown

Making Old Drugs New Again with Specialized Biotech: DURECT Corp.'s James E. Brown
Source: George S. Mack of The Life Sciences Report  (1/27/16)
Sometimes wonderful ideas live on and create value for the ages. Alza Corp. was a pioneer in the field of drug delivery, and that illustrious heritage continues in its spinout, DURECT Corp., which has leveraged the technology to enable highly innovative, value-added products that may soon be on the market. In this interview with The Life Sciences Report, DURECT cofounder and CEO James E. Brown discusses his company's pipeline, and how DURECT is evolving into a high-margin, blockbuster biotech. More >


James Joyce

Aethlon Medical CEO Jim Joyce Discusses the Forthcoming 'Concussion' Movie and CTE Research Being Conducted by Aethlon's Exosome Sciences Subsidiary
Source: Gail Dutton of The Life Sciences Report  (12/22/15)
Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc. (AEMD:NASDAQ), is pioneering the potential use of an exosome-based biomarker to diagnose chronic traumatic encephalopathy (CTE), a condition that otherwise can only be identified postmortem. As James "Jim" Joyce, executive chairman, tells The Life Sciences Report, other companies are exploring this approach in oncology, but Exosome Sciences is the only company advancing an exosome-based candidate to diagnose CTE. More >


Andrew Gengos

An Immunotherapeutic Approach to Glioblastoma: ImmunoCellular Therapeutics' CEO Andrew Gengos
Source: George S. Mack of The Life Sciences Report  (12/16/15)
Los Angeles-based ImmunoCellular Therapeutics Ltd. is on the verge of a pivotal Phase 3 trial with its dendritic cell immunotherapy for brain cancer. It's an extraordinary and exciting time for CEO Andrew Gengos, who is a veteran biotech executive. In this interview with The Life Sciences Report, Gengos discusses his firm's recently reported Phase 2 data in glioblastoma, as well as the company's strategy for the upcoming registration trial. More >


Cary Vance

Robotics Are Key to New Millennium Surgeries: Hansen Medical's Cary Vance
Source: Gail Dutton of The Life Sciences Report  (11/13/15)
Interventional radiology has been described as the surgery of the new millennium by Stanford Healthcare, offering less invasive procedures, more precise placement of catheters and, often, fewer complications for patients and higher throughput for healthcare facilities. Robotics is making this new area of medicine possible. Cary G. Vance, CEO of Hansen Medical Inc., tells The Life Sciences Report about disruptive advances in interventional radiology and Hansen's own revolutionary robotic catheters. More >


Shawn Patrick O'Brien

How Cipher Pharmaceuticals Is Developing Products for Dermatological Disorders
Source: Dan Levy for The Life Sciences Report  (11/4/15)
Skin disorders encompass a broad class of medical indications, from psoriasis to melanoma. Many companies focus on developing treatments for specific dermatological indications, but few have been able to build product portfolios with the range of therapeutic and consumer products currently marketed by Cipher Pharmaceuticals. In this interview with The Life Sciences Report, Shawn Patrick O'Brien, president and CEO of Cipher, describes his company's ongoing efforts to address unmet needs in dermatology. More >


James Joyce

Aethlon Medical's Biofiltration Platform Tackles Everything from Ebola to Cancer: CEO James Joyce
Source: Gail Dutton of The Life Sciences Report  (10/28/15)
Aethlon Medical Inc. has pioneered a novel biofiltration platform that was used effectively against Ebola in 2014. Now this broad-spectrum platform is being tested against cancer and other life-threatening diseases. Aethlon CEO James "Jim" Joyce tells The Life Sciences Report how this device is helping transform modern healthcare. More >


Rik Deitsch

OTC Strategy Supports Cobra Venom Pipeline in Asia and North America: Nutra Pharma's Rik Deitsch
Source: Gail Dutton of The Life Sciences Report  (10/21/15)
A strategy of over-the-counter sales helps derisk Nutra Pharma Corp. as it advances a therapeutic pipeline based on cobra toxin. In this interview with The Life Sciences Report, CEO Rik Deitsch elaborates how he plans to grow the company through distribution of Nutra Pharma's pain medications in India, China, Canada and the U.S., and how therapies based on the toxin can address a variety of autoimmune diseases. More >


Ross Macdonald

Delivering the Triple Whammy that Makes Stem Cell Therapies Commercially Viable: Cynata Therapeutics' Ross Macdonald
Source: Gail Dutton of The Life Sciences Report  (10/14/15)
Stem cell therapies have been slowed by high production costs, batch-to-batch variability and limited seed material. Ross Macdonald, CEO of Cynata Therapeutics, tells The Life Sciences Report how his company's innovative manufacturing methods can generate robust, consistent and inexpensive stem cells, and how this technology is likely to accelerate the commercialization of stem cell therapies worldwide. More >


Joseph Wagner Charles Wiseman Saeid Babaei

Breakthrough Potential: BriaCell Therapeutics Takes Its Cancer Vaccine to the Next Level
Source: Gail Dutton of The Life Sciences Report  (9/30/15)
Immuno-oncology has the potential to not only transform medicine, but also to become a multibillion-dollar market for a drug developer with the right team and the right compound. In this interview with The Life Sciences Report, BriaCell Therapeutics Corp. executives Joseph Wagner, Charles Wiseman and Saeid Babaei describe their company's new therapeutic, which has generated stunning results in early trials, making "breakthrough" designation by the FDA a realistic possibility. More >


Robert Erwin

The Promise of Plants in Pharmaceutical Production: iBio's Robert Erwin
Source: Gail Dutton of The Life Sciences Report  (9/9/15)
The growing need for recombinant proteins for vaccines and therapeutics is causing the biotech industry to look beyond vat fermentation and cell cultures for protein expression systems that, like iBio Inc.'s iBioLaunch technology, can increase yields quickly, safely and inexpensively. In this interview with The Life Sciences Report, iBio's President Robert L. (Bob) Erwin describes the iBioLaunch technology and what it offers to drug developers and investors. More >


Donald McCaffrey

Disrupting Treatment of Cardiovascular Disease with Epigenetics: Resverlogix CEO Donald McCaffrey
Source: Gail Dutton of The Life Sciences Report  (8/26/15)
The evidence is mounting: Resverlogix Corp.'s first-in-class, epigenetics-based drug candidate has demonstrated its ability to significantly reduce major adverse cardiac events (MACE)—death, heart attacks, strokes and heart failure, particularly in diabetic patients—in three consecutive clinical trials. That, company President and CEO Donald McCaffrey tells The Life Sciences Report, is why RVX-208 will likely be a blockbuster. More >


Showing Results: 1 to 25 of 50 Next

More Experts